Compile Data Set for Download or QSAR
Report error Found 86 Enz. Inhib. hit(s) with all data for entry = 225
TargetTyrosine-protein kinase JAK1(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234970(n-(cyanomethyl)-4-(5-methyl-2-((4-(4-(2-oxopyrroli...)
Affinity DataIC50: 0.600nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234972(n-(cyanomethyl)-4-(5-methyl-2-((4-(4-(5-methyl-1,3...)
Affinity DataIC50: 1.20nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234969(n-(cyanomethyl)-4-(5-methyl-2-((4-(4-morpholinopip...)
Affinity DataIC50: 1.30nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234967(4-(2-((4-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)p...)
Affinity DataIC50: 1.5nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234971(4-(2-((4-(4-(1-oxa-8-azaspiro[4.5]decan-8-yl)piper...)
Affinity DataIC50: 2.5nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234970(n-(cyanomethyl)-4-(5-methyl-2-((4-(4-(2-oxopyrroli...)
Affinity DataIC50: 2.5nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234972(n-(cyanomethyl)-4-(5-methyl-2-((4-(4-(5-methyl-1,3...)
Affinity DataIC50: 2.60nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234969(n-(cyanomethyl)-4-(5-methyl-2-((4-(4-morpholinopip...)
Affinity DataIC50: 2.80nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234943(n-(cyanomethyl)-4-(2-((4-(4-(1,1-dioxidoisothiazol...)
Affinity DataIC50: 4nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234971(4-(2-((4-(4-(1-oxa-8-azaspiro[4.5]decan-8-yl)piper...)
Affinity DataIC50: 4.30nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234967(4-(2-((4-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)p...)
Affinity DataIC50: 4.30nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234973(n-(cyanomethyl)-4-(5-fluoro-2-((4-(4-morpholinopip...)
Affinity DataIC50: 4.90nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234959(n-(cyanomethyl)-4-(2-((4-(4-(tetrahydro-2h-[1,4]di...)
Affinity DataIC50: 5nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234957(4-(2-((4-(4-(1-oxa-8-azaspiro[4.5]decan-8-yl)piper...)
Affinity DataIC50: 5nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234968(4-(2-((4-(4-(6-acetyl-3,6-diazabicyclo[3.1.1]hepta...)
Affinity DataIC50: 5nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234957(4-(2-((4-(4-(1-oxa-8-azaspiro[4.5]decan-8-yl)piper...)
Affinity DataIC50: 5nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234943(n-(cyanomethyl)-4-(2-((4-(4-(1,1-dioxidoisothiazol...)
Affinity DataIC50: 5.10nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234942(n-(cyanomethyl)-4-(2-((4-(4-(2-oxopyrrolidin-1-yl)...)
Affinity DataIC50: 5.60nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234960(n-(cyanomethyl)-4-(2-((4-(4-(2-oxo-1-oxa-8-azaspir...)
Affinity DataIC50: 6nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234946(n-(cyanomethyl)-4-(2-((4-(4-morpholinopiperidin-1-...)
Affinity DataIC50: 6.60nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234966(n-(cyanomethyl)-4-(2-((4-(4-(5-methyl-1,3,4-oxadia...)
Affinity DataIC50: 6.70nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234973(n-(cyanomethyl)-4-(5-fluoro-2-((4-(4-morpholinopip...)
Affinity DataIC50: 6.70nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234956(4-(2-((4-(4-(1,3,4-oxadiazol-2-yl)piperidin-1-yl)p...)
Affinity DataIC50: 7nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234954(4-(2-((4-(4-(6-oxa-3-azabicyclo[3.1.1]heptan-3-yl)...)
Affinity DataIC50: 8nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234958(n-(cyanomethyl)-4-(2-((4-(4-(5-methyl-1,3,4-oxadia...)
Affinity DataIC50: 8nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234951(n-(cyanomethyl)-4-(2-((4-(4-(1,1-dioxidotetrahydro...)
Affinity DataIC50: 8nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234968(4-(2-((4-(4-(6-acetyl-3,6-diazabicyclo[3.1.1]hepta...)
Affinity DataIC50: 8.80nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234955(n-(cyanomethyl)-4-(2-((4-(4-(2-oxoimidazolidin-1-y...)
Affinity DataIC50: 9nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234966(n-(cyanomethyl)-4-(2-((4-(4-(5-methyl-1,3,4-oxadia...)
Affinity DataIC50: 9.20nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234959(n-(cyanomethyl)-4-(2-((4-(4-(tetrahydro-2h-[1,4]di...)
Affinity DataIC50: 10nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234956(4-(2-((4-(4-(1,3,4-oxadiazol-2-yl)piperidin-1-yl)p...)
Affinity DataIC50: 10nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234970(n-(cyanomethyl)-4-(5-methyl-2-((4-(4-(2-oxopyrroli...)
Affinity DataIC50: 10.7nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234955(n-(cyanomethyl)-4-(2-((4-(4-(2-oxoimidazolidin-1-y...)
Affinity DataIC50: 11nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234960(n-(cyanomethyl)-4-(2-((4-(4-(2-oxo-1-oxa-8-azaspir...)
Affinity DataIC50: 11nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234953(n-(cyanomethyl)-4-(2-((4-(4-(tetrahydro-2h-pyran-4...)
Affinity DataIC50: 11nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234963(n-(cyanomethyl)-4-(2-((4-(4-(4,5-dihydro-1h-imidaz...)
Affinity DataIC50: 11nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234946(n-(cyanomethyl)-4-(2-((4-(4-morpholinopiperidin-1-...)
Affinity DataIC50: 11.7nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234950(n-(cyanomethyl)-4-(2-((4-(4-(1,1-dioxidotetrahydro...)
Affinity DataIC50: 12nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234958(n-(cyanomethyl)-4-(2-((4-(4-(5-methyl-1,3,4-oxadia...)
Affinity DataIC50: 12nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234942(n-(cyanomethyl)-4-(2-((4-(4-(2-oxopyrrolidin-1-yl)...)
Affinity DataIC50: 12.1nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234954(4-(2-((4-(4-(6-oxa-3-azabicyclo[3.1.1]heptan-3-yl)...)
Affinity DataIC50: 13nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234964(n-(cyanomethyl)-4-(2-((4-(4-(4,5-dihydro-1h-imidaz...)
Affinity DataIC50: 13nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234950(n-(cyanomethyl)-4-(2-((4-(4-(1,1-dioxidotetrahydro...)
Affinity DataIC50: 14nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234951(n-(cyanomethyl)-4-(2-((4-(4-(1,1-dioxidotetrahydro...)
Affinity DataIC50: 14nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234961(n-(cyanomethyl)-4-(2-((4-(4-(5-oxo-4,5-dihydro-1,3...)
Affinity DataIC50: 15nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234965(n-(cyanomethyl)-4-(2-((4-(3-(tetrahydro-2h-[1,4]di...)
Affinity DataIC50: 15nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234949(4-(2-((4-([1,3'-bipyrrolidin]-1'-yl)phenyl)amino)p...)
Affinity DataIC50: 16nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234953(n-(cyanomethyl)-4-(2-((4-(4-(tetrahydro-2h-pyran-4...)
Affinity DataIC50: 16nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234973(n-(cyanomethyl)-4-(5-fluoro-2-((4-(4-morpholinopip...)
Affinity DataIC50: 16.6nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Cadila Healthcare

US Patent
LigandPNGBDBM234948(4-(2-((4-(4-(1h-1,2,4-triazol-1-yl)piperidin-1-yl)...)
Affinity DataIC50: 17nMT: 2°CAssay Description:NCEs were screened using in vitro JAK (1, 2 and 3) kinase assay on ADP Glo platform (Promega). Fixed amount of recombinant purified human JAK (25 ng ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

Displayed 1 to 50 (of 86 total ) | Next | Last >>
Jump to: